Skip to main content
Retour
Watch Compare

Aprea Therapeutics, Inc.

Qualité des données : 83%
APRE
Nasdaq Manufacturing Chemicals
0,72 €
▲ 0,02 € (2,62%)
Cap. Boursière: 8,25 M
Prix
0,72 €
Cap. Boursière
8,25 M
Fourchette du Jour
0,67 € — 0,74 €
Fourchette 52 Semaines
0,55 € — 2,22 €
Volume
103 832
Ouverture 0,74 €
Moyenne 50J / 200J
0,75 €
4,26% below
Moyenne 50J / 200J
1,24 €
41,81% below

Quick Summary

Points Clés

Negative free cash flow of -12,91 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-103,58%
En dessous de la moyenne du secteur (-53,41%)
ROIC-81,10%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio5,20
Interest CoverageN/A

Valorisation

PE (TTM)
-0,65
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,76
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,7 -1,5
P/B 0,8 1,6
ROE % -103,6 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12,60 M
ROE -103,58% ROA -79,67%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12,91 M
ROIC -81,10% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,20
Interest Coverage N/A Asset Turnover N/A
Working Capital 11,26 M Tangible Book Value 10,91 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,65 Forward P/E N/A
P/B Ratio 0,76 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -156,56%
Market Cap 8,25 M Enterprise Value -5,47 M
Per Share
EPS (Diluted TTM) -1,93 Revenue / Share N/A
FCF / Share -1,13 OCF / Share -1,13
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 102,46%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -12,60 M -12,96 M -14,29 M -112,66 M -37,13 M
EPS (Diluted) -1,93 -2,45 -3,95 -68,16 -1,74
Gross Profit — — — — —
Operating Income -13,23 M -14,32 M -15,47 M — —
EBITDA — — — — —
R&D Expenses — — — — 23,90 M
SG&A Expenses — — — — —
D&A 21 715,0 22 318,0 7 052,0 4 403,0 12 829,0
Interest Expense — — — — —
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15,93 M 23,98 M 22,65 M 30,16 M 56,82 M
Total Liabilities — — — 3,20 M 7,32 M
Shareholders' Equity 12,44 M 19,31 M 16,95 M 25,64 M 49,51 M
Total Debt — — — — —
Cash & Equivalents 14,60 M 22,85 M 21,61 M 28,79 M 53,08 M
Current Assets 15,56 M 23,58 M 22,52 M 30,15 M 56,58 M
Current Liabilities 2,76 M 3,36 M 4,39 M 3,20 M 7,32 M